



Corporate Presentation

November 2025



Safe harbor and forward-looking statements



This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: whether Arvinas' product candidates will address two areas of significant unmet need for patients; Arvinas' plans related to its clinical trials and preclinical studies and the timings thereof; Arvinas' novel proteolysis targeting chimera ("PROTAC") therapeutic modality being potentially first to market in breast cancer; Arvinas' capitalization, and having cash runway into the second half of 2028; Arvinas' assets' intended differentiation from other therapies; Arvinas' best-in-class research engine setting Arvinas up for long-term impact; the continued potential to leverage partnerships to enhance the value of Arvinas' pipeline; Arvinas' potential receipt of milestone payments from existing partners, including Novartis; novel PROTAC approach having first-in-class promise and potential to differentiate from existing and emerging modalities in, and potentially revolutionize the treatment of, neurodegenerative diseases; PROTAC-induced leucine-rich repeat kinase 2 ("LRRK2") degradation having the potential to differentiate from kinase inhibition; PROTAC-induced LRRK2 degradation as a potential treatment for idiopathic Parkinson's disease and progressive supranuclear palsy; that a PROTAC expanded polyglutamine androgen receptor degrader may eliminate the root cause of disease for SBMA; Arvinas' plans, anticipated milestones, timings and potential impacts of such milestones, related to its neurology pipeline candidates, including ARV-102 and ARV-027; the potential for a PROTAC B-cell lymphoma 6 ("BCL6") degrader to address substantial unmet needs for patients with non-Hodgkin Lymphoma ("NHL"); the potential for ARV-393 to become an attractive combination partner for development of novel treatment approaches for NHL, including all oral or chemotherapy-free options; any dose escalation potential in the Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory NHL; the potential for ARV-806, Arvinas' novel PROTAC Kirsten rat sarcoma ("KRAS") G12D degrader, to be a best-in-class therapy for patients with KRAS G12D mutated cancers and to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer; the potential for vepdegestrant to be a first- and best-in-class treatment monotherapy option in second-line, estrogen receptor 1 ("ESR1") mutant, estrogen receptor positive ("ER+")/human epidermal growth factor receptor 2 negative ("HER2-") advanced or metastatic breast cancer; Arvinas' plans, anticipated milestones, timing and potential impacts of such milestones, related to its oncology pipeline candidates, including ARV-393, ARV-806, vepdegestrant and ARV-6723; PROTAC degraders having potential benefits that may provide advantages over other modalities in oncology and neurology; and Arvinas' anticipated milestones in the second half of 2025 and in 2026 in connection with ARV-102, ARV-393, ARV-806, vepdegestrant and its preclinical candidates. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "goal," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, ARV-393 and ARV-806, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials on expected timelines, or at all; whether Arvinas will be able to successfully conduct and complete development for preclinical candidates, including ARV-027 and ARV-6723, including whether Arvinas initiates and completes preclinical studies and receives results from such studies on expected timelines, or at all; whether Arvinas and Pfizer will be able to successfully conduct clinical development for vepdegestrant as a monotherapy; risks and uncertainties related to the joint selection between Arvinas and Pfizer of a third party for the commercialization and potential further development of vepdegestrant; risks related to obtaining marketing approval for and commercializing vepdegestrant and other product candidates; Arvinas' ability to protect its intellectual property portfolio; risks associated with Arvinas' reliance on third parties; the risk that Arvinas' previously announced workforce reductions may affect its ability to retain skilled and motivated personnel and may be distracting to employees and management; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors, any of which could cause Arvinas' actual results to differ from those contained in the forward-looking statements, discussed in the "Risk Factors" sections of Arvinas' quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect Arvinas' current views as of the date of this presentation with respect to future events, and the company assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this presentation.

The Arvinas name and logo are the company's trademarks. The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Arvinas has omitted the ® and designations, as applicable, for the trademarks named in this presentation.

This presentation may also contain estimates and other statistical data made by independent parties and by Arvinas relating to market size and other data about the company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of the company's future performance and the future performance of the markets in which the company operates are necessarily subject to a high degree of uncertainty and risk. This presentation is intended for the investor community only. It is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Cross-trial comparisons are not based on head-to-head studies and no direct comparisons can be made.



IGNITING A
**TRANSFORMATIVE
CHANGE**

in the fight for patients with cancer
and neurodegenerative diseases



Our experienced and talented team is advancing a new therapeutic modality for patients



Promising preclinical results are translating into the clinic



6 programs entered clinical trials in 5 years^a, targeting significant unmet needs for patients

History of FIRSTS with our novel **PROTAC** therapeutic modality:

Discovery

Clinical trials in oncology

Clinical trials in neuroscience

Positive Phase 3 topline readout

Potentially first to market in breast cancer

Strong, experienced leadership team



Expertise from bench to commercialization

AR and ER degraders highlight Arvinas' ability to develop valuable PROTAC degraders



ER: vepdegestrant^a Pfizer

- Positive efficacy and well-tolerated in Phase 1, 2 and 3 clinical trials
 - First positive Phase 3 trial and first new drug application (NDA) submitted to U.S. FDA with a PROTAC
- Potential to be a best-in-class treatment monotherapy option in 2L, ESR1m, ER+/HER2- advanced or metastatic BC
 - NDA filed by FDA with PDUFA date of June 5, 2026

AR: luxdegalutamide NOVARTIS

- Demonstrated signals of efficacy in late-line prostate cancer suggests potential for positive efficacy in earlier-line settings
- Out-licensed to Novartis in 2024 with potential for more than \$1B in total deal value
- Novartis is currently evaluating luxdegalutamide in 3 Phase 2 combination trials in mCRPC and mHSPC




Strategic clinical-stage partnerships with Pfizer and Novartis have resulted in more than \$800M in non-dilutive cash

AR, androgen receptor; ER, estrogen receptor; BC, breast cancer; ESR1, estrogen receptor 1 gene; ER+/HER2-, estrogen receptor-positive/human epidermal growth factor receptor 2-negative; FDA, Food and Drug Administration;

mCRC, metastatic castrate resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PDUFA, Prescription Drug User Fee Act

a. In 2021, Arvinas entered into a collaboration agreement with Pfizer to co-develop and co-commercialize vepdegestrant

PROTAC degraders harness the body's natural machinery to degrade, not simply inhibit, disease-causing proteins



PROTAC degraders have potential benefits that may provide advantages over other modalities in oncology and neurology



BENEFITS IN ONCOLOGY

- ✓ Ability to overcome evolving resistance mechanisms
- ✓ Targeting of classically “undruggable” proteins
- ✓ Therapies with potential to improve upon existing treatment options



BENEFITS OF PROTAC PROTEIN DEGRADERS

- ✓ Elimination (rather than inhibition) of disease-causing proteins
- ✓ Interruption of scaffolding functions of target proteins
- ✓ Iterative (catalytic) activity
- ✓ Oral delivery and broad tissue distribution
- ✓ Mutant and/or wild-type specificity
- ✓ Efficient manufacturing and routes of synthesis (versus biologics and cell therapies)

BENEFITS IN NEUROLOGY

- ✓ Blood-brain barrier penetration
- ✓ Oral administration, avoiding IM, IV, or intrathecal dosing
- ✓ Biodistribution to deep-brain regions



Seeking to address two of the largest areas of significant unmet need for patients




ONCOLOGY

By 2040

30M >>^{Leading to}>> **15M**

New cancer cases per year worldwide¹

Cancer-related deaths per year¹



1 in 8
US women will develop breast cancer in their lifetime²

Despite progress, cancer remains one of the most common causes of death³ and new treatments are needed


NEUROLOGY

By 2040

neurodegenerative diseases will be the

#2

LEADING CAUSE OF DEATH
in developed countries⁴



people with Parkinson's disease worldwide⁵

Well-known, but poorly drugged targets represent strong potential for effective treatments

1. Global Cancer Observatory: <https://gco.iarc.fr/tomorrow/en/dataviz/isotype?years=2040>; accessed 10/25/25. 2. ACS: <https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer>; accessed 10/25/25. 3. World Health Organization: <https://www.who.int/news-room/fact-sheets/detail/cancer>; accessed 10/25/25. 4. Nature: <https://doi.org/10.1038/nj7526-299a>; accessed 10/25/25. 5. Parkinson's Foundation: <https://www.parkinson.org/understanding-parkinsons/statistics>; accessed 10/25/25.

Arvinas pipeline includes differentiated PROTAC degraders in neurology and oncology



PROGRAM	INDICATION	PRECLINICAL	PHASE 1/1B	PHASE 2	PHASE 3	MARKET
ARV-102 (LRRK2)	NEUROLOGY		Phase 1: Parkinson's disease			
ARV-027 (polyQ-AR)	NEUROLOGY		Spinal Bulbar Muscular Atrophy			
ARV-393 (BCL6)	ONCOLOGY		Phase 1 monotherapy: NHL ^a			
ARV-806 (KRAS G12D)	ONCOLOGY		Phase 1: Solid tumors harboring KRAS G12D mutations			
ARV-6723 (HPK1)	ONCOLOGY		I-O Indications			
Vepdegestrant (ARV-471; ER)	ONCOLOGY		Phase 3 VERITAC-2: NDA filed ^b Phase 1/2 combination trials ongoing ^c			Seeking 3 rd party for commercialization and future development
Luxdegalutamide (ARV-766, JSB462; AR)	ONCOLOGY		Phase 2: mHSPC and mCRPC			Global rights licensed to

These agents are currently under investigation; their safety and effectiveness for these investigational uses have not been established.

AR, androgen receptor; BCL6, B-cell lymphoma 6; ER, estrogen receptor; HPK1, Hematopoietic Progenitor Kinase 1; I-O, immuno-oncology; KAT6, lysine acetyltransferase 6; KRAS, Kirsten rat sarcoma viral oncogene homolog; LRRK2, leucine-rich repeat kinase 2; mCRPC, metastatic castration resistant prostate cancer; mHSPC, metastatic hormone sensitive prostate cancer; NDA, new drug application; NHL, non-Hodgkin lymphoma; polyQ, expanded polyglutamine;

a. Includes relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL) and relapsed/refractory mature B cell NHL; b. Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2026 c. Phase 1/2 combination trials with palbociclib, atromiciclib, abemaciclib, ribociclib, samuraciclib, everolimus.

Strategically positioned for the next stage of growth



High-Value Pipeline of Differentiated Programs

- Delivering innovative assets intended to differentiate from other therapies; investing in highest value drivers across the pipeline
- Best-in-class research engine sets up Arvinas for long-term impact
- Continued potential to leverage partnerships to enhance the value of Arvinas' pipeline



Pivotal Proof of Concept with Vepdegestrant

- Vepdegestrant is an investigational and potential first-in-class oral PROTAC estrogen receptor degrader
- Positive pivotal VERITAC-2 data presented at ASCO 2025; NDA under review by the U.S. FDA^a
- Seeking a 3rd party for the commercialization and potential further development of vepdegestrant



Strong Capitalization

- Cash runway into 2H 2028^b
- Multiple value-inflecting milestones ahead, with potential to receive milestone payments from existing partners, including NOVARTIS

ASCO, American Society of Clinical Oncology; NDA, new drug application

a. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application submission for vepdegestrant and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2026; b. Based on cash, cash equivalents, and marketable securities position as of September 30, 2025




CLINICAL PROGRAMS: Neurology

ARV-102 PROTAC LRRK2 degrader



ARV-102 is an investigational compound. Its safety and effectiveness have not been established.


Neurodegenerative diseases: An area of tremendous unmet need



Unmet need is high:

- No approved disease-modifying therapies for multiple important target proteins (e.g., LRRK2, tau, α -synuclein) implicated in the pathology of various neurodegenerative diseases⁴
- Blood-brain barrier penetration is a challenge for other modalities (e.g., antibodies and antisense oligonucleotides)
- Other existing and potential therapies have difficult routes of administration, e.g., intrathecal, intracerebral

PROTAC degraders could potentially revolutionize the treatment of neurodegenerative diseases



A novel PROTAC approach with first-in-class promise and potential to differentiate from existing and emerging modalities in neurodegenerative diseases

a. In preclinical and clinical studies, dose-dependent increases in exposure in cerebral spinal fluid after single and multiple doses of ARV-102 indicated brain penetration.

LRRK2 in Parkinson's disease and progressive supranuclear palsy



Parkinson's Disease (PD)

- Neurodegenerative disorder that affects movement, balance, and coordination
- Mutations in the LRRK2 gene are one of the most common genetic causes of PD; variants have also been observed in idiopathic cases¹
- Increased LRRK2 expression and activity contributes to neurodegeneration and pathogenesis of idiopathic PD,¹ making it a rational therapeutic target



**No approved
disease-modifying
therapies exist
for patients with
PD or PSP**

Progressive Supranuclear Palsy (PSP)

- Rare progressive neurological disorder that affects movement, balance, and cognitive function
- Characterized by tauopathy (accumulation of abnormal forms of the microtubule-associated protein tau)²
- Preclinical data indicate that LRRK2 mutations are associated with tau pathology resembling PSP²
- Genetic variations in LRRK2 are associated with PSP progression, highlighting the potential importance of LRRK2 in tauopathies²



Given its role in neurodegeneration, Arvinas is exploring LRRK2-targeting PROTAC degraders as possible treatments for PD, PSP, and related disorders

PROTAC-induced LRRK2 degradation as a potential treatment for idiopathic Parkinson's disease and progressive supranuclear palsy




Progressive supranuclear palsy (PSP) is a tauopathy with rapid progression to death within 5-7 years

- Increased LRRK2 drives tau accumulation, neurotoxicity, and cGAS/STING-mediated neuroinflammation.
- LRRK2 genetic variants raise expression and accelerate disease progression.
- Reducing LRRK2 protein or kinase activity limits tau oligomers and spread in animal models and human neurons.

Parkinson's disease (PD) is the second-largest tauopathy

- Familial and sporadic LRRK2 variants drive PD and tau pathology; G2019S enhances tau and α -synuclein spread.
- LRRK2, a multidomain kinase, disrupts lysosomal clearance (α Syn and tau pathology).
- Levels are ~2x higher in CSF and microglia in iPD, and reducing LRRK2 by 50% improves pathology, α -synuclein, neuronal death, and dysfunction in models.

Mutations and increased expression of LRRK2




Human genetics and biology create a strong rationale for differential biology of PROTAC LRRK2 degraders

cGAS/STING, cyclic GMP-AMP synthase/stimulator of interferon genes; CSF, cerebral spinal fluid; G2019S, specific genetic mutation in the LRRK2 gene, known as Glycine to Serine at position 2019; LRRK2, leucine-rich repeat kinase 2; PD, Parkinson's disease; PSP, progressive supranuclear palsy

Wang, 2021; Zhao, 2017; Henderson, 2019; Zheng, 2022; Cacace MJFF 2024; Li et al., 2021; Yoon et al., 2017; Gregory et al., 2024; Kluss et al. Biochem Soc Trans. 2019;47:651-61. 2. Herbst et al. Clin Sci 2022;136:1071-1079.; Bentley-DeSousa et al., 2025;

PROTAC-induced LRRK2 degradation has the potential to differentiate from kinase inhibition

LRRK2 is a large multidomain scaffolding kinase




PROTAC LRRK2 degrader differentiates from inhibitors

	Inhibitor	PROTAC
Kinase activity	✓	✓
GTPase activity	✗	✓
Signaling scaffold	✗	✓
Increased protein level	✗	✓

LRRK2 single nucleotide polymorphisms are associated with elevated LRRK2 levels in patients with Parkinson's disease¹ and Progressive Supranuclear Palsy²

ARV-102 increases lysosome functional degradative capacity and number in cells

Lysosome function and number are reduced in patients with PD^a and models; ARV-102 dose-dependently increased degradation efficiency and lysosome number vs kinase inhibitors




- Mutant familial PD and increased LRRK2 expression ‘puts the brakes’ on lysosomal clearance system
- Autophagy (clearance dependent on lysosome) is reduced with increased LRRK2 expression, LRRK2 familial mutation (G2019S), and LRRK2 activity/levels in rodent neurons^b
- LRRK2 PROTAC activity is consistent with literature showing an increase in lysotracker spot count observed in LRRK2 KO astrocytes^c

LRRK2, Leucine-rich repeat kinase 2; PD, Parkinson’s disease; KO, genetic knock out; DQ-BSA, Dye Quenched-Bovine Serum Albumin

a. Dehey et al., 2013. Lysosomal impairment in Parkinson’s disease; b. R. Wallings et al., 2019; c. Henry et al., 2015

Data presented at 2023 Keystone Summit: Autophagy and Neurodegeneration


In vitro and *in vivo* data suggest that Arvinas' LRRK2 PROTAC degraders can reduce PSP-induced pathologic tau




ARV-102 shows better target engagement, enhanced potency, and pathway engagement versus a LRRK2 inhibitor in G2019S KI mice



Iterative and catalytic PROTAC advantage results in stronger LRRK2 reduction and RAB pathway engagement versus a LRRK2 kinase inhibitor^a



50x greater *target engagement* with ARV-102



50x greater *pathway engagement* with ARV-102

a. G2019S familial Parkinson's Disease mouse model.


LRRK2, Leucine-rich repeat kinase 2

Data presented at 2023 Keystone Summit: Autophagy and Neurodegeneration.


Arvinas previously showed that ARV-102 degrades LRRK2 in NHP deep-brain regions and that CSF levels of LRRK2 track cortex LRRK2



Orally dosed ARV-102 reaches multiple “deep brain” regions in nonhuman primates (NHPs) and **degrades** LRRK2 up to 94%




In NHPs, CSF levels of LRRK2 can be used to indicate levels of LRRK2 in cortex



Potential LRRK2-dependent protein pathway biomarker discovery utilizing PPMI and LRRK2 PROTAC degrader treated NHP CSF




Global analysis of SomaScan data from PPMI vs ported NHP CSF/ ARV-102 study




Identified proteins enriched in pathways related to neuroinflammatory response and lysosomal function

IBA1, Cathepsin B, and GPNMB were identified as LRRK2-dependent pathway biomarkers that concord with LRRK2 protein levels in NHP CSF



CSF, cerebral spinal fluid; GPNMB, transmembrane glycoprotein identified as a "Damage-associated Microglia" neurodegenerative protein; IBA1, microglia marker, also known as "Allograft Inflammatory Factor 1 (AIF-1); LRRK2, Leucine-rich repeat kinase 2; NHP, non-human primates; PPMI, Parkinson's Progression Markers Initiative
a. B Phillips, 2023



Putative LRRK2 biomarkers associated with disease are reduced in non-human primate CSF after dosing with ARV-102



In healthy volunteers, dose-dependent increases in ARV-102 and LRRK2 reductions in CSF indicate brain penetration and target engagement

ARVINAS

ARV-102 induced dose-dependent reductions in LRRK2 levels in CSF, with >50% LRRK2 reduction at single doses ≥ 60 mg (*data not shown*) and repeated doses ≥ 20 mg




CSF, cerebrospinal fluid; IQR, interquartile range; LLOQ, lower limit of quantification; LRRK2, leucine-rich repeat kinase 2; MAD, multiple ascending dose; SAD, single ascending dose; SISCAPA, stable isotope standards and capture by anti-peptide antibodies. LRRK2 detected by SISCAPA. Circles indicate individual values. Box plot provides median and 25%/75% quartiles with whiskers to the last point within 1.5 times the IQR. Values below LLOQ (~5 pg/mL; shown in red) were calculated as half of LLOQ. Participants who received placebo across cohorts in SAD or MAD were pooled. Values shown are 24 hours post-dose.

In healthy volunteers, multidose ARV-102 treatment led to reductions in downstream LRRK2 pathway biomarkers in blood cells and urine



Phospho-Rab10^{T73} in PBMCs




Rab10, a GTPase involved in the lysosomal stress response, is a LRRK2 substrate and biomarker for downstream LRRK2 pathway engagement^{1–6}

BMP is a lysosomal lipid and a sensitive biomarker for the LRRK2 lysosome pathway in urine^{1–4}


ARV-102 at single doses \geq 30 mg resulted in >50% decreases in phospho-Rab10^{T73} and BMP in urine

BMP Lysosomal Lipid in Urine




Changes from baseline in (A) phospho-Rab10T73 levels in PBMCs 6 hours after the 14th dose and (B) BMP levels in urine obtained between 6 and 8 hours after the 14th dose of ARV-102 or placebo. In panel A, 3 participants (20 mg, n=2; placebo, n=1) were excluded due to lack of baseline data. Circles indicate individual values. Box plots show median and 25%/75% quartiles with whiskers to the last point within 1.5 times the interquartile range. Values below the LLOQ (shown in red) were calculated as half of the LLOQ. BMP=bis(monoacylglycerol) phosphate; LLOQ=lower limit of quantification; LRRK2=leucine-rich repeat kinase 2; MAD=multiple ascending dose; PBMCs=peripheral blood mononuclear cells.

In healthy volunteers, ARV-102 led to significant reductions in lysosomal pathway markers when compared to placebo



CSF CD68 – example of dose-dependent reductions



- ARV-102 reduced lysosomal markers (CTSH, TMEM106A, GRN, GPNMB, CD68), reflecting effects on proteolysis, lysosomal integrity, and microglial activation—supporting normalization of the ‘leaky lysosome’ hypothesis in neurodegeneration.
- Reduction of C1QTNF1 and ENTPD1 by LRRK2 PROTAC reflects normalization of cytokine and purinergic signaling, dampening neuroinflammation in PD.

P values (***P*<0.01; ****P*<0.001) were calculated using unpaired t-tests vs placebo. Circles indicate individual values. Box plots show median and 25%/75% quartiles with whiskers to the last point within 1.5 times the interquartile range.



Unbiased proteomic analyses utilizing the SomaScan platform were conducted on CSF samples from participants who received ARV-102 or placebo QD for 14 days in the phase 1 healthy volunteer study.

C1QTNF1, complement C1q tumor necrosis factor-related protein 1; CD68, cluster of differentiation 68; CFB, change from baseline; CSF, cerebrospinal fluid; CTSH, cathepsin H; ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1; GRN, granulin precursor; GPNMB, glycoprotein non-metastatic melanoma protein B; LRRK2, leucine-rich repeat kinase 2; TMEM106A, transmembrane protein 106A.

In patients with Parkinson's, exposure of ARV-102 in plasma and CSF increased in a dose-dependent manner, indicating brain penetration



ARV-102 exposure (AUC_{inf} and C_{max}) increased in a dose-dependent manner in plasma and in CSF




Data are preliminary and were tabulated manually. In the left panel, circles indicate individual values and box plots show median and 25%/75% quartiles with whiskers to the last point within 1.5 times the interquartile range. CSF data were obtained 28 to 30 hours post-dose.

CSF, cerebrospinal fluid

In patients with Parkinson's, ARV-102 decreased LRRK2 protein levels in PBMCs after a single oral dose

Median LRRK2 levels in PBMCs **decreased 86%** from baseline following a single 50-mg dose of ARV-102 and **97%** after a 200-mg dose



Note: Data are preliminary and were calculated manually.

Data shown are % change from baseline in LRRK2 protein levels in PBMCs obtained 24 hours after a single dose. Circles indicate individual patient values. Box plots show median and 25%/75% quartiles with whiskers to the last point within 1.5 times the interquartile range.

Values below the lower limit of quantification (LLOQ, shown in red) are plotted as half of the LLOQ.

LRRK2, leucine-rich repeat kinase 2; PBMCs, peripheral blood mononuclear cells.

Development plan for ARV-102 includes clinical trials in patients with Parkinson's disease and progressive supranuclear palsy



Status of ARVINAS Trials with ARV-102

OBJECTIVES: Safety, Tolerability, PK, and PD

Study ARV-102-101 HEALTHY VOLUNTEERS		Study ARV-102-103 PARKINSON'S DISEASE	
SINGLE ASCENDING DOSE Part A; Complete	✓	MULTIPLE ASCENDING DOSE Part B; Complete	✓
✓ First-in-human data presented during oral presentation at AD/PD (Q2 2025)		✓ Final data from HV SAD/MAD cohorts ✓ Presented at MDS (07-Oct-25)	✓ Enrollment complete ✓ Presenting initial single ascending dose data ✓ Presented at MDS (08-Oct-25) • Multi-dose cohort in Parkinson's disease (Part B) ongoing



Initiation of Phase 1b trial in patients with progressive supranuclear palsy planned in 2026



PRECLINICAL PROGRAMS: Neurology


ARV-027
PROTAC polyQ-AR degrader

ARVINAS

Spinal bulbar muscular atrophy is caused by a trinucleotide CAG repeat expansion in the androgen receptor


Spinal bulbar muscular atrophy (SBMA) is rare, genetically defined, neuromuscular disease

- X-linked inheritance pattern and caused by a polyglutamine (polyQ) expansion in the androgen receptor (AR)
- Clinical features result from both the loss of normal androgen signaling and gain of toxic properties due to the polyQ-expansion
- PolyQ-AR ultimately causes death of myofibers by apoptosis, leading to progressive muscle weakness and loss of motor neurons
- SBMA prevalence is estimated between 5.5-20K patients in the U.S.¹




SBMA is a multisystemic disease and patients suffer from progressive debilitating neuromuscular symptoms¹

SBMA Disease Overview



SBMA Natural History and Treatment Options

Onset typically occurs between 35 – 55 years old, with hand tremors and limb weakness being the most common initial manifestations



Life expectancy is modestly impacted (brugada / aspiration pneumonia), but disability severely impacts patients

There are no approved therapies for SBMA in the U.S.


Current treatment focuses on symptom management only, including physical therapy and rehabilitation

High unmet need for disease-modifying therapy to slow down the disease progression or reverse disease biology


ARV-027 is a potent *in vitro* and *in vivo* PROTAC degrader of polyQ-AR, the root cause of SBMA¹



ARV-027 induces degradation of polyQ-AR in myotubes derived from SBMA patient induced pluripotent stem cells







ARV-027 induces degradation of AR in muscle tissue from male mice



The mechanism of the polyQ AR degradation was confirmed to be E3 ligase and proteosome dependent (data not shown)

In preclinical models, ARV-027 induced polyQ-AR degradation in muscle tissues and rescued strength and endurance



polyQ-AR, polyglutamine-expanded (polyQ) androgen receptor (AR); SBMA, spinal bulbar muscular atrophy

a. AR100Q mice

Gregory J et al., International Congress of the World Muscle Society (WMS), Poster 718LBP. Presented October 10, 2025



CLINICAL PROGRAMS: Hematology-Oncology

ARV-393

PROTAC BCL6 degrader



ARV-393 is an investigational compound. Its safety and effectiveness have not been established.

A PROTAC BCL6 degrader has the potential to address substantial unmet needs for patients with non-Hodgkin lymphoma (NHL)



**Key Unmet Needs
for Patients with
Non-Hodgkin
Lymphomas**

Safe and effective oral alternatives to chemotherapy or immuno-chemotherapy standard of care regimens for patients with relapsed disease, high risk disease, and particularly older adults.

Heterogeneous nature of disease leads to variable patient outcomes.

Therapies based on actionable biomarkers are needed.

Large B-Cell Lymphoma (LBCL)

- Although a high proportion of patients achieve complete remission, therapy resistance or relapse still occurs in 30–40% of patients, thus evidencing a need for new therapeutic options¹
- Deregulation of BCL6 expression and/or functions are common in B-cell lymphomas²


Follicular Lymphoma (FL)

- Lack of effective options for patients who experience rapid disease progression within 2 years of initial therapy (POD24)
- In ~15% of patients, indolent FL transforms into clinically aggressive lymphoma with rapid progression of disease and poor prognosis³
- BCL6 mutation is associated with the transformation of FL

Other Subtypes of NHL

- T-cell lymphomas dependent on BCL6 (family of nodal T-follicular helper cell Lymphomas, nTFHL⁴)
- nTFHL-AI (nTFHL, angioimmunoblastic type⁴), also known as AITL, is a rare and aggressive disease with no dedicated approved therapies and high levels of BCL6 expression⁵

Uncontrolled activation of BCL6 is implicated in development of B-cell lymphomas




The Importance of BCL6 in Lymphoma

- **Master Regulator –** BCL6 represses genes that control cell proliferation, survival, and apoptosis during B-cell maturation
- **Disrupts B-Cell Function –** Deregulated BCL6 alters cell signaling and cycle control, preventing proper B-cell differentiation
- **Drives Malignant Transformation –** Abnormal BCL6 activity enables B-cells to evade regulatory mechanisms, leading to lymphoma

ARV-393 is an investigational oral PROTAC degrader that degrades BCL6, a classic “undruggable” protein



ARV-393



Potent, orally bioavailable PROTAC small molecule degrader of BCL6¹



Degrades BCL6, a target that has long been considered “undruggable”



Differentiated preclinical profile. ARV-393 **potently and rapidly degrades** BCL6 protein and has iterative activity, which is critical to overcoming BCL6’s rapid resynthesis rate and sustaining antitumor activity




Demonstrated significant anti-tumor single-agent activity¹ and broad combinability with complete tumor regressions in combination with SOC biologics and investigational small molecule agents in numerous preclinical *in vivo* models of NHL², with potential to become an **attractive combination partner** for development of novel treatment approaches for NHL including **all oral or chemotherapy-free options**

A Phase 1 monotherapy dose escalation trial of ARV-393 is currently enrolling patients with relapsed/refractory NHL (NCT06393738)

ARV-393 potently degrades BCL6 in human lymphoma cell lines




ARV-393, but not its E3-inactive analogue, robustly degrades BCL6 in the OCI-Ly1 model of DLBCL



Semi-quantitative western blot of BCL6 degradation by ARV-393


The E3-inactive analogue of ARV-393 cannot engage the E3 ligase and does not degrade BCL6, confirming ARV-393 degradation is mediated by PROTAC mechanism

ARV-393 exhibits picomolar degradation potency in quantitative immunocapture assay in multiple DLBCL cell lines




Preclinically, ARV-393 rapidly degrades BCL6 and overcomes its high resynthesis rate that drives tumor cell growth

BCL6 protein is resynthesized rapidly – nearly back to baseline levels at 2 hours post-ARV-393 washout



OCI-Ly1 cells were treated with 1.5 nM ARV-393 for 4 hours. Duplicate samples are shown following ARV-393 washout and addition of cereblon ligand (to block residual ARV-393)


ARV-393 rapidly degrades >90% of BCL6 within 2 hours - degrading BCL6 faster than the cell can resynthesize it



	DC ₅₀ [nM]	D _{max}
2 hours	0.05	93%
4 hours	0.03	94%
24 hours	0.03	97%


ARV-393 induces dose-dependent and sustained tumor growth inhibition and regressions *in vivo*

ARV-393 induces dose-dependent and sustained TGI in OCI-Ly1 DLBCL CDX model




- Tumor regression at 30 mg/kg dosed once per day (QD)
- No adverse impact on animal health/body weight (body weight not shown)

ARV-393 demonstrated >90% TGI



- TGI assessment of different dosing regimens of ARV-393 in the OCI-Ly1 CDX model demonstrate tumor growth inhibition >90% after 22 days at 10 and 30 mg/kg dosing





Preclinically, BCL6 degradation by ARV-393 drives antitumor activity by increasing gene expression normally repressed by BCL6



- BCL6 Repression –** BCL6 is a transcriptional repressor and expression of PTPN6, IRF4, and CDKN1B are repressed by it
- Pathway Activation –** Treatment with ARV-393 increased the expression of PTPN6, IRF4, and CDKN1B, indicating BCL6 pathway engagement, collectively driving antitumor effects

Single agent ARV-393 induces tumor growth inhibition in PDX models of various non-Hodgkin lymphoma subtypes

Breadth of efficacy beyond DLBCL demonstrated in multiple patient-derived xenograft (PDX) models with no body weight loss^a



Similar results seen in fifteen PDX models of various NHL subtypes

4 mice/group, PO QDx21
 Vehicle
 ARV-393 30 mg/kg

ABC, activated B cell-like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell-like; NHL, non-Hodgkin's lymphoma; PDX, patient derived xenograft model; tFL, transformed follicular lymphoma; TGI, tumor growth inhibition

*molecular classification according to LymphGen analysis, Wright et al., 2020. Gough et al., European Hematology Association (EHA) Poster P1256. June 2024, Madrid Spain. Van Acker et al., European Hematology Association (EHA) Poster PF1000. June 2025, Milan Italy.


a. Body weight not shown.

First preclinical evidence of efficacy with a BCL6-targeted degrader in a patient-derived model of a rare T-cell lymphoma with a high unmet need




ARV-393 demonstrates evidence of significant efficacy (comparable to SOC romidepsin) in a chemo (CHOP) relapsed AITL PDX model


Peripheral Blood



Bone Marrow



Spleen



P<0.01; *P<0.005; ****P<0.0001

AITL, angioimmunoblastic T-cell lymphoma, also known as nodal T-follicular helper cell lymphoma, angioimmunoblastic-type; BCL6, B cell lymphoma 6; CHOP, Cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone; ns, not significant; SOC, standard of care; PDX, patient-derived xenograft

Van Acker et al., European Hematology Association (EHA) Poster PF1000. June 2025, Milan Italy.

ARV-393 has the potential to be an attractive combination partner for development of novel treatment options for non-Hodgkin lymphoma



CHEMOTHERAPY-FREE AND IMPROVED CHEMOTHERAPY OPTIONS

- Standard of Care Chemotherapy
 - R-CHOP
- Standard of Care Biologics
 - CD19 (tafasitamab)
 - CD79b (polatuzumab vedotin)
 - CD20 (rituximab)
 - CD20xCD3 (glofitamab)

CHEMOTHERAPY-FREE AND ALL ORAL OPTIONS

- Small molecule inhibitors
 - BTK (acalabrutinib)
 - BCL2 (venetoclax)
 - EZH2 (tazemetostat)


ARV-393 Combinations *In Vivo* DLBCL models




In preclinical models of aggressive DLBCL, ARV-393 demonstrated broad combinability, with tumor regressions observed in combination with SOC chemotherapy, SOC biologics and investigational oral small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma

ARV-393 demonstrates activity in combination with SOC chemotherapy/biologics and drives tumor regressions, including complete responses, in a preclinical model of aggressive DLBCL


R-CHOP




Rituximab



Tafasitamab



Polatuzumab vedotin






All data is in SU-DHL-4 high grade (triple hit) CDX model of diffuse large B-cell lymphoma

CDX, cell-derived xenograft; DLBCL, diffuse large B-cell lymphoma; IV, Intravenous; PO, oral; QD, once a day; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone; SOC, standard of care

a. Rituximab 3 mg/kg was administered intravenously (IV) on days 1, 8, 15, and 22; CHOP (30:2.475:0.375:0.15 mg/kg) was given IV on day 1 (prednisone was given PO QD on days 1–5). b. Tafasitamab was administered IV on days 1, 4, 8, 15 and 22. *P<0.05; **P<0.005;

****P<0.0001 (one-way ANOVA, Tukey's multiple comparisons); Acker et al., American Association for Cancer Research (AACR) Poster 1655/15. April 2025, Chicago.

ARV-393 demonstrates activity in combination with small molecule inhibitors and drives tumor regressions, including complete responses, in preclinical models of aggressive DLBCL



ABC, activated B-cell; BID, twice a day; CDX, cell-derived xenograft; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; IV, Intravenous; PO, oral; QD, once a daily

P<0.01; *P<0.005; ****P<0.0001 (one-way ANOVA, Tukey's multiple comparisons)

Anna Van Acker et al., American Association for Cancer Research (AACR) Poster 1655/15. April 2025, Chicago; Van Acker et al., European Hematology Association (EHA) Poster PF1000. June 2025, Milan Italy.

Arvinas is currently enrolling a Phase 1 clinical trial of ARV-393 in relapsed/refractory non-Hodgkin lymphoma



Previously treated adult patients with relapsed/refractory mature B-cell NHL or nTFHL-AI

Sequential assignment

28-day treatment cycles



Dose escalation of ARV-393 orally

Dose may be escalated to higher dose cohorts or de-escalated to lower dose cohorts based on the safety and tolerability as per a Cohort Review Committee recommendation

- ARV-393 is being evaluated in an open-label, first-in-human Phase 1 dose escalation study to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in adult patients with relapsed/refractory NHL (NCT: 06393738)



CLINICAL PROGRAMS: Oncology

ARV-806

PROTAC KRAS G12D degrader

ARVINAS

ARV-806 is an investigational compound. Its safety and effectiveness have not been established.

ARV-806 is a novel PROTAC KRAS G12D degrader with the potential to be a best-in-class therapy



KRAS
G12D



KRAS is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer.

ARV-806 is a novel, investigational PROTAC **degrader** that is designed to target both the ON and OFF forms of the KRAS G12D protein


There are no approved drugs for KRAS G12D mutated cancers, where patients have high unmet need and poor survival outcomes

ARV-806 is differentiated from other **G12D targeting agents** in development and has potential to be a best-in-class therapy for KRAS G12D mutated cancers due to:

- Catalytic activity (overcomes upregulation, a common mechanism of resistance to inhibitor treatment)
- Preclinically, ARV-806 demonstrated >40-fold higher potency in degrading KRAS G12D protein vs the comparable clinical-stage G12D degrader
- Preclinically, ARV-806 demonstrated >25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS G12D ON and OFF inhibitors and a clinical-stage G12D degrader

A Phase 1 clinical trial is currently enrolling patients with advanced solid tumors harboring KRAS G12D mutations (NCT07023731)

KRAS is a key regulator of cell growth, and KRAS mutations lead to cancer



Role of KRAS G12D in Cancer^{1,2}

- KRAS is a GTPase that alternates between inactive and active states, regulating several critical signaling pathways
- Mutations in KRAS, such as G12D, lock the protein in the active "ON" state, leading to uncontrolled cell growth and cancer development
- KRAS G12D is the most frequent KRAS mutation and one of the most common mutations across various cancer types

1. Huang, L., Guo, Z., Wang, F. et al., *Sig Transduct Target Ther* 6, 386 (2021). <https://doi.org/10.1038/s41392-021-00780-4>.

2. Lee et al., *NPJ Precis. Oncol.*, 2022; Cox et al., *Nat Rev Drug Dis.* 2014. Vasan et al., 2014, *Clin Cancer Res.*

Patients with metastatic cancers harboring KRAS G12D mutations have poor survival outcomes with no approved KRAS G12D-targeted therapy





Key Tumors Harboring KRAS G12D Mutations	5-year Survival Rate for Metastatic Setting	Newly Diagnosed Patients Per Year in the US (2024) ¹	Prevalence of KRAS G12D Mutations
 Pancreatic ductal adenocarcinoma	3%	~66,000	~35 - 40% ^{2,3}
 Colorectal carcinoma	16%	~153,000	~12 - 15% ^{2,3}
 Non-small cell lung cancer	6%	~200,000	~3 - 4% ^{2,3,4}

G12D, mutations in codon 12 on KRAS oncogene; KRAS, Kirsten rat sarcoma (a frequently mutated oncogene in cancers)

1. SEER Database, Decision Resource Group 2024 Epi Data: Annual US incidence of newly diagnosed metastatic patients harboring KRAS G12D mutation 2 Lee et al., NPJ Precis. Oncol., 2022, 3 AACR Genie, 4 Acker et al., Frontiers in Oncol., 2021

ARV-806 targets both ON and OFF forms of KRAS G12D


- ARV-806 forms a ternary complex with **both** OFF (GDP-bound) and ON (GTP-bound) KRAS G12D
 - Targeting both OFF and ON KRAS G12D allows ARV-806 to **eliminate** this oncogenic protein from the cell
- ARV-806 treatment directly leads to ubiquitination of KRAS G12D protein




Preclinical data show ARV-806 is a highly potent, selective degrader of KRAS G12D

ARV-806 degrades KRAS G12D with picomolar potency

Degradation of KRAS G12D in GP2d Colorectal Cancer Cells




Degradation of KRAS G12D Multiple Cancer Cell Lines²



ARV-806 effectively eliminates KRAS G12D from cancer cells

ARV-806 is selective for KRAS G12D

Degradation of RAS Measured by HiBit Signal³





ARV-806 demonstrates exquisite selectivity for KRAS G12D, indicating a robust therapeutic index

G12D, mutations in codon 12 on KRAS oncogene; KRAS, Kirsten rat sarcoma (a frequently mutated oncogene in cancers); RAS, rat sarcoma

1. Concentrations of ARV-806: 3 nM – 3 pM; 2. Data from western blot of endogenous KRAS G12D levels; 3. Cell lines bearing HiBit-tagged variants of KRAS and NRAS were assessed for degradation when treated with ARV-806

Smith K et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) Poster B107. Presented October 24, 2025, Boston

Preclinically, ARV-806 demonstrates anti-proliferative activity approximately 25 times greater than KRAS inhibitors and the leading clinical-stage degrader




G12D, mutations in codon 12 on KRAS oncogene; KRAS, Kirsten rat sarcoma (a frequently mutated oncogene in cancers)

1. Treatment for 24 hours; 2. AsPC-1 (G12D/G12D) pancreatic cancer cells treated for 5 days; 3. GP2d (G12D/WT) colorectal cancer cells treated for 5 days

Smith K et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) Poster B107. Presented October 24, 2025, Boston

ARV-806 more potently induces pancreatic cancer cell death *in vitro* relative to clinical-stage inhibitors and degrader





Treatments were for 24 hours

BIM, Bcl-2-interacting mediator of cell death (a pro-apoptotic factor); G12D, mutations in codon 12 on KRAS oncogene; KRAS, Kirsten rat sarcoma (a frequently mutated oncogene in cancers)

Smith K et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) Poster B107. Presented October 24, 2025, Boston

ARV-806 leads to robust and extended degradation and signaling suppression *in vivo*



G12D, mutations in codon 12 on KRAS oncogene; KRAS, Kirsten rat sarcoma (a frequently mutated oncogene in cancers)




a. Single IV dose of 3 mpk ARV-806 administered to mice bearing colorectal cancer tumors (GP2d xenograft model)

Smith K et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) Poster B107. Presented October 24, 2025, Boston


ARV-806 demonstrated robust responses at low doses in models of colorectal, pancreatic, and non-small cell lung cancers



$\geq 30\%$ tumor volume reductions in pancreatic and colorectal CDX models and a patient-derived xenograft (PDX) model of lung cancer



A Phase 1/2 clinical trial of ARV-806 in KRAS G12D-mutated advanced solid tumors is currently enrolling



ARV-806 is being evaluated in an open-label, first-in-human Phase 1/2 clinical trial to assess its safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity in adult patients with KRAS G12D-mutated advanced solid tumors (NCT: 07023731)



CLINICAL PROGRAMS: Oncology

Vepdegestrant (ARV-471)

Investigational PROTAC estrogen receptor degrader

Vepdegestrant is an investigational compound. Its safety and effectiveness have not been established.



Unmet need in ER+/HER2- metastatic breast cancer

ER+/HER2- breast cancer accounts for approximately

70%

of all breast cancer cases and is driven in part by the ER signaling pathway.¹



ER pathway mediates the transcription of genes that promote tumor cell growth, proliferation, and survival²



First-line treatments for ER+/HER2- advanced or metastatic breast cancer are typically endocrine therapies combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor³




No clear standard of care in the second-line-plus (2L+) setting; new treatment options are needed

Despite clinical improvements with these first-line therapies, patients often experience treatment resistance and experience disease progression.⁴


1. Surveillance, Epidemiology, and End Results Program Data, <https://seer.cancer.gov/statfacts/html/breast-subtypes.html>. 2. Chen P (2022) Role of estrogen receptors in health and disease. *Front. Endocrinol.* 13:839005. doi: 10.3389/fendo.2022.839005. 3. ESMO Guidelines, [https://www.annalsofoncology.org/article/S0923-7534\(21\)04498-7/pdf](https://www.annalsofoncology.org/article/S0923-7534(21)04498-7/pdf) Citation: Gennari A, et al., *Ann Oncol.* 2021;32. 4. American Association for Cancer Research, <https://aacrjournals.org/cancerdiscovery/article/10/8/1174/2810/The-Genomic-Landscape-of-Intrinsic-and-Acquired>. doi: 10.1158/2159-8290.CD-19-1390.

VEPDEGESTRANT: Potential first PROTAC estrogen receptor degrader



- Vepdugestrant is the first PROTAC to be evaluated in a Phase 3 pivotal study, VERITAC-2
 - VERITAC-2 data presented at ASCO 2025, and simultaneously published in the New England Journal of Medicine, showed:
 - Vepdugestrant was well tolerated, with low rates of discontinuation
 - Vepdugestrant met its primary endpoint of improvement in progression-free survival versus the standard of care, fulvestrant, in previously-treated patients with ESR1m, ER+/HER2- advanced breast cancer
 - Patient reported outcomes data demonstrate that vepdugestrant significantly reduced risk of deterioration in measures of overall health status compared to fulvestrant in patients with ESR1 mutations
 - More than 1,000 patients and healthy volunteers have been treated with vepdugestrant across the clinical program
- **Vepdugestrant is an investigational drug with the potential to be a best-in-class treatment option for previously treated patients with ESR1 mutant ER+/HER2- advanced or metastatic breast cancer**

Vepdegestrant has the potential to be best-in-class treatment in the 2L+, ESR1 mutant setting



EFFICACY MEASURES

~2.4x

Improvement in mPFS over fulvestrant

~3-month

Improvement in mPFS
(5.0m vs. 2.1m)
vs. fulvestrant



TOLERABILITY

- Favorable safety/tolerability profile
- Low rates and severity of GI-related events
- Low rate of discontinuation (2.9%)




REAL-WORLD APPLICABILITY

- Patient characteristics of those enrolled in VERITAC-2 were representative of real-world 2L setting
 - 100% prior CDK4/6i + ET, pre/peri menopausal

VERITAC-2: Global Phase 3 clinical trial of vepdegestrant

Key Eligibility Criteria

- Age ≥ 18 years old
- ER+/HER2- advanced or metastatic breast cancer
- Prior therapy:
 - 1 line of CDK4/6i + ET
 - ≤ 1 additional ET
 - Most recent ET for ≥ 6 months
 - No prior SERD (eg, fulvestrant, elacestrant)
 - No prior chemotherapy for advanced or metastatic disease
- Radiological progression during or after the last line of therapy



Primary Endpoints:

- PFS by BICR in
 - *ESR1m* population
 - All patients

Secondary Endpoints:

- OS (key secondary)
- CBR and ORR by BICR
- AEs

Data cutoff date: Jan 31, 2025
 Clinicaltrials.gov: NCT05654623

Baseline characteristics of the VERITAC-2 population representative of the real-world second-line setting in the U.S.




Characteristic	Patients With ESR1m		All Patients	
	Vepdегestrant (n=136)	Fulvestrant (n=134)	Vepdегestrant (n=313)	Fulvestrant (n=311)
Median age (range), y	60 (26–87)	60 (34–85)	60 (26–89)	60 (28–85)
Female, %	99	100	99	100
Postmenopausal, %	79	79	78	78
Race, %				
White	43	51	47	46
Black or African American	3	4	2	2
Asian	45	37	39	41
Unknown/NR	9	7	12	9
ECOG PS, %				
0	57	57	61	64
1	43	43	39	36
ESR1m, % ^a	100	100	43	43
Sites of disease, %				
Visceral disease	68	68	63	63
Liver metastasis	46	44	40	36
Bone-only disease	18	18	18	20


Characteristic, %	Patients With ESR1m		All Patients	
	Vepdегestrant (n=136)	Fulvestrant (n=134)	Vepdегestrant (n=313)	Fulvestrant (n=311)
Measurable disease ^b	71	75	71	71
Prior lines of therapy in advanced/metastatic setting ^c				
1	82	80	82	76
2	18	20	18 ^d	23 ^d
Prior endocrine therapy	100	100	100	100 ^e
Aromatase inhibitor	99	100	99	99
SERM	15	16	16	20
Prior CDK4/6 inhibitor	100	100	100	100
Palbociclib	50	54	46	52
Ribociclib	38	28	36	31
Abemaciclib	16	25	20	21
Other ^f	1	5	4	4

CDK4/6, cyclin-dependent kinase 4/6; ECOG PS, Eastern Cooperative Oncology Group performance status; ESR1m, estrogen receptor 1 gene mutation; NR, not reported; SERD, selective estrogen receptor degrader; SERM, selective estrogen receptor modulator
a. ESR1m status was assessed in pretreatment circulating tumor DNA; b. measurable disease assessed by blinded independent central review using Response Evaluation Criteria for Solid Tumors v1.1; c. disease progression during or within 12 months from the end of adjuvant therapy was counted as a line of therapy in the advanced/metastatic setting; d. one additional patient in the vepdегestrant group and 3 additional patients in the fulvestrant group received 3 prior lines of therapy; e. one patient received a prior SERD. f. other CDK4/6 inhibitors included birociclib, dalpiciclib, lerociclib

Vepdegestrant met the primary endpoint with a ~3-month mPFS improvement in patients with tumors harboring *ESR1* mutations



Vepdegestrant showed statistically significant improvements in CBR and ORR in the *ESR1* mutant population



BICR, blinded independent central review; CBR, clinical benefit rate; CR, complete response; *ESR1m*, estrogen receptor gene 1 mutation; ORR, objective response rate; PR, partial response; SD, stable disease

a. CBR was defined as the rate of confirmed CR or PR at any time, or SD, non-CR, or non-progressive disease for ≥24 weeks and was estimated in CBR-evaluable patients (those enrolled for ≥24 weeks prior to data cutoff or those with confirmed CR or PR). b. ORR was defined as the rate of confirmed CR or PR and was estimated in patients with measurable disease at baseline. c. Nominal p-value.

Vepdegestrant was generally well-tolerated, with low rates of discontinuation and dose reductions; majority of TRAEs Gr 1/2

Overview

TEAEs, %	Vepdegestrant (n=312)	Fulvestrant (n=307)
Any grade	87	81
Grade ≥3	23	18
Serious	10	9
Leading to treatment discontinuation	3	1
Leading to dose reduction	2	NA
TRAEs, %		
Any grade	57	40
Grade ≥3	8	3

QT prolongation

- TEAEs: vepdegestrant, 10%; fulvestrant, 1%
- A QT interval sub-study (n=88) confirmed a mild increase (11.1 ms) from baseline in mean QTcF, with upper 90% CI (13.7 ms) <20 ms,^f indicating no large QT-prolonging effect

TEAEs in >10% of Patients in Either Group

TEAE, %	Vepdegestrant (n = 312)	Fulvestrant (n = 307)		
	Any Grade	Grade 3/4	Any Grade	Grade 3/4
Fatigue ^a	27	1	16	1
ALT increased ^b	14	1	10	1
AST increased ^b	14	1	10	3
Nausea	13	0	9	1
Anemia ^{b, c}	12	2	8	3
Neutropenia ^d	12	2 ^e	5	1 ^e
Back pain	11	1	7	<1
Arthralgia	11	1	11	0
Decreased appetite	11	<1	5	0

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; QTcF, corrected QT interval using Fridericia's method; TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event


a. Includes fatigue and asthenia. b. No between-group differences were observed for ALT/AST increases or anemia based on laboratory values. c. Includes anemia, hemoglobin decreased, and iron deficiency anemia. d. Includes neutropenia and neutrophil count decreased. No events led to dose reductions or treatment discontinuation in either treatment group. There were no events of febrile neutropenia in the vepdegestrant group and 1 event of grade 2 febrile neutropenia in the fulvestrant group. e. One patient with grade 4 event. f. Based on a concentration-QTc population modeling analysis.

Vepdugestrant significantly reduced risk of clinically meaningful definitive deterioration in measures of overall health status compared to fulvestrant in patients with ESR1 mutations


VERITAC-2: Patient Reported Outcomes in patients with ESR1 mutations

TTDD in EORTC QLQ-C30

GHS/QoL



TTDD in EQ-5D-5L VAS




HRs and their 95% CIs were calculated using a Cox regression model stratified by visceral disease status at baseline (yes/no), with fulvestrant as a reference. P values were calculated using a stratified log-rank test that accounted for the stratification by visceral disease status.

EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EQ-5D-5L= EuroQoL 5-dimension, 5-level; GHS, global health status; HR, hazard ratio; QoL, quality of life; TTDD, time to definitive clinically meaningful deterioration; VAS, visual analog scale.

The risk of clinically meaningful deterioration in pain was significantly lower with vepdegestrant compared to fulvestrant across all pain measures evaluated in patients with ESR1 mutations




VERITAC-2: Patient Reported Outcomes in patients with ESR1 mutations



a. HRs and their 95% CIs were calculated using a Cox regression model stratified by visceral disease status at baseline (yes/no), with fulvestrant as a reference; b. P values were calculated using a stratified log-rank test that accounted for the stratification by visceral disease status.

BPI-SF, Brief Pain Inventory Short Form; HR, hazard ratio; NE, not estimable; TTDD, time to definitive deterioration.

Vepdegestrant has potential to be a best-in-class treatment in *ESR1* mutant ER+/HER2- advanced or metastatic breast cancer




Novel treatment options are needed for the ~20k patients^a in the US with *ESR1*-mutated ER+/HER2- advanced or metastatic breast cancer in the 2L+ setting

In VERITAC-2, vepdegestrant demonstrated 5-month median PFS, with **robust 2.9-month improvement over fulvestrant** in patients with tumors harboring *ESR1* mutations

Vepdegestrant's novel mechanism of action as a PROTAC ER degrader differentiates it from other ER targeting therapies in the 2L+ *ESR1* mutant setting

Positive results from VERITAC-2 Phase 3 clinical trial support potential registration^a



Potential to address high unmet need for patients with tumors harboring an ESR1 mutation in 2L+ setting

Vepdegestrant showed a clinically meaningful median PFS benefit over fulvestrant, a current standard of care, in patients with ESR1 mutations

Vepdegestrant's safety and tolerability provide further evidence of a potential best-in-class profile

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application submission for vepdegestrant

**FDA assigned a Prescription Drug User Fee Act (PDUFA)
target action date of June 5, 2026**

Arvinas is a leader in developing PROTAC degraders with potential best-in-class profiles, with multiple upcoming value-driving milestones

PROTAC degraders designed to provide advantages over other modalities in oncology and neurology

	2H 2025 Anticipated Milestones	2026 Anticipated Milestones
ARV-102 LRRK2 degrader	<ul style="list-style-type: none">Initial Phase 1 SAD data in PDInitiate multiple dose cohort in PD	<ul style="list-style-type: none">Phase 1 MAD data in PDInitiate Phase 1b in PSP
ARV-393 BCL6 degrader	<ul style="list-style-type: none">Phase 1 mono trial updatePreclinical combination data	<ul style="list-style-type: none">Interim Phase 1 data (mono)Initiate Phase 1 combo
ARV-806 KRAS G12D degrader	<ul style="list-style-type: none">Preclinical data	<ul style="list-style-type: none">Initial Phase 1 data
Vepdegestrant	<ul style="list-style-type: none">File NDA	<ul style="list-style-type: none">PDUFA Action
Pre-Clinical		<ul style="list-style-type: none">Initiate Phase 1: ARV-027 (polyQ-AR; SBMA)Initiate Phase 1: ARV-6723 (HPK1; advanced solid tumors)

Strong capital position with ~\$788M cash on hand^a and runway into second half 2028

The agents listed on this slide are investigational. Their safety and effectiveness for these investigational uses have not been established.

BCL6, B-cell lymphoma 6; G12D, mutations in codon 12 on KRAS oncogene; HPK1, hematopoietic progenitor kinase 1; KRAS, Kirsten rat sarcoma; LRRK2, leucine-rich repeat kinase 2; NDA, new drug application; SAD, single ascending dose; MAD, multiple ascending dose; PD, Parkinson's disease; PDUFA, Prescription Drug User Fee Act; polyQ-AR, polyglutamine-expanded (polyQ) androgen receptor (AR); PSP, progressive supranuclear palsy; SBMA, spinal bulbar muscular atrophy.

a. Cash, cash equivalents, and marketable securities position as of September 30, 2025.



FOR MORE INFORMATION

Press/Media | pr@arvinas.com

Investors | ir@arvinas.com

Business Development | bd@arvinas.com

Careers | [careers@arvinas.com](mailtocareers@arvinas.com)

